Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. histologically or cytologically confirmed diagnosis of any advanced or metastatic relapsed or refractory solid tumor.~Exclusion criteria:~1. Active brain metastases~2. Patients with known pre-existing interstitial lung disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Afatinib and docetaxel (Type: None): None
- Afatinib and gemcitabine (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).